The OSIRIS-REx spacecraft's name has been changed to OSIRIS-APEX for its new mission to asteroid Apophis. See its journey to ...
Last year delivered doses of drama and excitement in the space business, with a record number of launches, breathtaking ...
IRVINE, Calif., Jan. 7, 2026 — Terran Orbital, a Lockheed Martin Company and a leading manufacturer of satellite solutions, announced today the appointment of Michael Vishion as vice president of ...
The Denver Creates fund has awarded a local animation studio a $10,000 grant to offer free animation courses to kids and adults. Since 2023, Mile High Animation has offered a summer camp and workshop ...
With outstanding customization options, an epic sensor, wireless connectivity, and stunningly lightweight, the Pathfinder is exemplary. Really, it's only mildly let down by its price and the fact that ...
Scientists Oppose Huge Array of Mirrors in Space That Shines Nighttime Sunlight on Wealthy Customers
These days, orbital real estate is growing increasingly cluttered with all manner of communication, observation, research, and navigation satellites. It’s a market worth $286 billion in 2022, ...
INDIANAPOLIS -- Indianapolis Colts backup quarterback Anthony Richardson suffered an orbital fracture to his eye prior to Sunday's 31-27 victory over the Arizona Cardinals, according to coach Shane ...
There’s something weird in the water in Indianapolis lately. The Colts had a couple of unusual injuries during pregame warmups before Sunday’s win over the Cardinals. Cornerback Charvarius Ward ...
Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results